• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于多组学分析的模型,用于预测低级别胶质瘤的预后。

A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.

作者信息

Du Zhijie, Jiang Yuehui, Yang Yueling, Kang Xiaoyu, Yan Jing, Liu Baorui, Yang Mi

机构信息

The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.

出版信息

Sci Rep. 2024 Apr 24;14(1):9427. doi: 10.1038/s41598-024-58434-8.

DOI:10.1038/s41598-024-58434-8
PMID:38658591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11043340/
Abstract

Lower-grade gliomas (LGGs) exhibit highly variable clinical behaviors, while classic histology characteristics cannot accurately reflect the authentic biological behaviors, clinical outcomes, and prognosis of LGGs. In this study, we carried out analyses of whole exome sequencing, RNA sequencing and DNA methylation in primary vs. recurrent LGG samples, and also combined the multi-omics data to construct a prognostic prediction model. TCGA-LGG dataset was searched for LGG samples. 523 samples were used for whole exome sequencing analysis, 532 for transcriptional analysis, and 529 for DNA methylation analysis. LASSO regression was used to screen genes with significant association with LGG survival from the frequently mutated genes, differentially expressed genes, and differentially methylated genes, whereby a prediction model for prognosis of LGG was further constructed and validated. The most frequently mutated diver genes in LGGs were IDH1 (77%), TP53 (48%), ATRX (37%), etc. Top significantly up-regulated genes were C6orf15, DAO, MEOX2, etc., and top significantly down-regulated genes were DMBX1, GPR50, HMX2, etc. 2077 genes were more and 299 were less methylated in recurrent vs. primary LGG samples. Thirty-nine genes from the above analysis were included to establish a prediction model of survival, which showed that the high-score group had a very significantly shorter survival than the low-score group in both training and testing sets. ROC analysis showed that AUC was 0.817 for the training set and 0.819 for the testing set. This study will be beneficial to accurately predict the survival of LGGs to identify patients with poor prognosis to take specific treatment as early, which will help improve the treatment outcomes and prognosis of LGG.

摘要

低级别胶质瘤(LGGs)表现出高度可变的临床行为,而经典的组织学特征无法准确反映LGGs的真实生物学行为、临床结局和预后。在本研究中,我们对原发性与复发性LGG样本进行了全外显子组测序、RNA测序和DNA甲基化分析,并结合多组学数据构建了一个预后预测模型。在TCGA-LGG数据集中搜索LGG样本。523个样本用于全外显子组测序分析,532个用于转录分析,529个用于DNA甲基化分析。使用LASSO回归从频繁突变基因、差异表达基因和差异甲基化基因中筛选与LGG生存显著相关的基因,从而进一步构建并验证LGG预后的预测模型。LGGs中最常发生突变的基因是IDH1(77%)、TP53(48%)、ATRX(37%)等。显著上调的前几位基因是C6orf15、DAO、MEOX2等,显著下调的前几位基因是DMBX1、GPR50、HMX2等。与原发性LGG样本相比,复发性LGG样本中有2077个基因甲基化程度更高,299个基因甲基化程度更低。将上述分析中的39个基因纳入建立生存预测模型,结果显示在训练集和测试集中,高分组合的生存期均显著短于低分组合。ROC分析表明,训练集的AUC为0.817,测试集的AUC为0.819。本研究将有助于准确预测LGGs的生存期,识别预后不良的患者以便尽早采取针对性治疗,这将有助于改善LGG的治疗效果和预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/8fdb15b335e2/41598_2024_58434_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/2b396bff7231/41598_2024_58434_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/f7107abb310c/41598_2024_58434_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/eecdb00e0596/41598_2024_58434_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/f1d618e7f4a8/41598_2024_58434_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/322c4ed54fa6/41598_2024_58434_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/f341659f997d/41598_2024_58434_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/797042bf5cda/41598_2024_58434_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/8fdb15b335e2/41598_2024_58434_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/2b396bff7231/41598_2024_58434_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/f7107abb310c/41598_2024_58434_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/eecdb00e0596/41598_2024_58434_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/f1d618e7f4a8/41598_2024_58434_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/322c4ed54fa6/41598_2024_58434_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/f341659f997d/41598_2024_58434_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/797042bf5cda/41598_2024_58434_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/03a2/11043340/8fdb15b335e2/41598_2024_58434_Fig8_HTML.jpg

相似文献

1
A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.一种基于多组学分析的模型,用于预测低级别胶质瘤的预后。
Sci Rep. 2024 Apr 24;14(1):9427. doi: 10.1038/s41598-024-58434-8.
2
SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.SHOX2是预测世界卫生组织II-III级弥漫性胶质瘤患者生存的有效独立生物标志物。
EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. Epub 2016 Oct 28.
3
An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.预测低级别胶质瘤预后的免疫相关标志物。
Front Immunol. 2020 Dec 8;11:603341. doi: 10.3389/fimmu.2020.603341. eCollection 2020.
4
Comparative genomic landscape of lower-grade glioma and glioblastoma.低级别胶质瘤和胶质母细胞瘤的比较基因组景观。
PLoS One. 2024 Aug 29;19(8):e0309536. doi: 10.1371/journal.pone.0309536. eCollection 2024.
5
An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.基于自噬基因的特征预测低级别胶质瘤患者的生存。
Cancer Med. 2021 Mar;10(5):1848-1859. doi: 10.1002/cam4.3748. Epub 2021 Feb 16.
6
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.2016年世界卫生组织弥漫性胶质瘤分类亚型的DNA甲基化特征
Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.
7
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.全外显子组测序确定ATRX突变是低级别胶质瘤的关键分子决定因素。
Oncotarget. 2012 Oct;3(10):1194-203. doi: 10.18632/oncotarget.689.
8
Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.磷脂酶 Cγ1(PLCG1)过表达与 IDH 野生型成人低级别胶质瘤的肿瘤生长和不良预后相关。
Lab Invest. 2022 Feb;102(2):143-153. doi: 10.1038/s41374-021-00682-7. Epub 2021 Oct 25.
9
Mitochondrial RNA modification-based signature to predict prognosis of lower grade glioma: a multi-omics exploration and verification study.基于线粒体 RNA 修饰的signature 预测低级别胶质瘤的预后:一项多组学探索和验证研究。
Sci Rep. 2024 Jun 1;14(1):12602. doi: 10.1038/s41598-024-63592-w.
10
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.CKS2(CDC28 蛋白激酶调节亚基 2)是低级别胶质瘤的预后生物标志物:基于生物信息学分析和免疫组织化学的研究。
Bioengineered. 2021 Dec;12(1):5996-6009. doi: 10.1080/21655979.2021.1972197.

引用本文的文献

1
Comprehensive multi-omics and machine learning framework for glioma subtyping and precision therapeutics.用于胶质瘤亚型分类和精准治疗的综合多组学与机器学习框架。
Sci Rep. 2025 Jul 10;15(1):24874. doi: 10.1038/s41598-025-09742-0.
2
Immune-Related Long Non-Coding RNA Signature Determines Prognosis and Immunotherapeutic Coherence in Esophageal Cancer.免疫相关长链非编码RNA特征决定食管癌的预后及免疫治疗一致性
Cancer Inform. 2024 Sep 12;23:11769351241276757. doi: 10.1177/11769351241276757. eCollection 2024.

本文引用的文献

1
[Cancer statistics in China, 2016].《2016年中国癌症统计数据》
Zhonghua Zhong Liu Za Zhi. 2023 Mar 23;45(3):212-220. doi: 10.3760/cma.j.cn112152-20220922-00647.
2
Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer.多基因panel 检测在结直肠癌患者中能发现高比例的临床可操作变异。
JCO Precis Oncol. 2022 Nov;6:e2200517. doi: 10.1200/PO.22.00517.
3
KEGG for taxonomy-based analysis of pathways and genomes.KEGG 用于基于分类的途径和基因组分析。
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592. doi: 10.1093/nar/gkac963.
4
N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.N6-甲基腺嘌呤去甲基酶 ALKBH5 通过降低 PHF20 mRNA 甲基化来抑制结直肠癌细胞的进展。
Clin Transl Med. 2022 Aug;12(8):e940. doi: 10.1002/ctm2.940.
5
Discovery and validation of tissue-specific DNA methylation as noninvasive diagnostic markers for colorectal cancer.发现和验证组织特异性 DNA 甲基化为结直肠癌的非侵入性诊断标志物。
Clin Epigenetics. 2022 Aug 16;14(1):102. doi: 10.1186/s13148-022-01312-9.
6
Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.多基因遗传性癌症风险评估 PREMMplus 模型的建立与验证。
J Clin Oncol. 2022 Dec 10;40(35):4083-4094. doi: 10.1200/JCO.22.00120. Epub 2022 Aug 12.
7
DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.DNA 甲基化亚类预测 IDH 野生型胶质母细胞瘤患者从全切除肿瘤中获益。
Neuro Oncol. 2023 Feb 14;25(2):315-325. doi: 10.1093/neuonc/noac177.
8
Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.多基因基因组分类器在可疑恶性细胞学甲状腺结节中的性能。
Thyroid. 2022 Dec;32(12):1500-1508. doi: 10.1089/thy.2022.0282. Epub 2022 Sep 1.
9
i-Modern: Integrated multi-omics network model identifies potential therapeutic targets in glioma by deep learning with interpretability.i-Modern:整合多组学网络模型通过具有可解释性的深度学习识别神经胶质瘤中的潜在治疗靶点。
Comput Struct Biotechnol J. 2022 Jun 30;20:3511-3521. doi: 10.1016/j.csbj.2022.06.058. eCollection 2022.
10
Inhibiting DNA methylation improves antitumor immunity in ovarian cancer.抑制 DNA 甲基化可改善卵巢癌的抗肿瘤免疫。
J Clin Invest. 2022 Jul 15;132(14). doi: 10.1172/JCI160186.